Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Sunshine Biopharma logo
$2.82
-0.03 (-1.05%)
(As of 10/31/2024 ET)

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Key Stats

Today's Range
$2.77
$2.90
50-Day Range
$2.80
$3.34
52-Week Range
$2.42
$640.00
Volume
113,241 shs
Average Volume
125,586 shs
Market Capitalization
$3.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Sunshine Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

SBFM MarketRank™: 

Sunshine Biopharma scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sunshine Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    16.08% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 13.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sunshine Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sunshine Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.08% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 13.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sunshine Biopharma has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Sunshine Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 2 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

  • Percentage Held by Institutions

    41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sunshine Biopharma's insider trading history.
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBFM Stock News Headlines

The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
See More Headlines

SBFM Stock Analysis - Frequently Asked Questions

Sunshine Biopharma's stock was trading at $27.15 at the start of the year. Since then, SBFM stock has decreased by 89.6% and is now trading at $2.82.
View the best growth stocks for 2024 here
.

Sunshine Biopharma, Inc. (NASDAQ:SBFM) issued its earnings results on Friday, August, 16th. The company reported ($9.94) EPS for the quarter. The company earned $9.30 million during the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 16.09% and a negative net margin of 12.07%.

Sunshine Biopharma shares reverse split on the morning of Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/16/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SBFM
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-4,510,000.00
Pretax Margin
-12.27%

Debt

Sales & Book Value

Annual Sales
$30.48 million
Book Value
$1,651.69 per share

Miscellaneous

Free Float
1,223,000
Market Cap
$3.49 million
Optionable
Not Optionable
Beta
1.39
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SBFM) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners